Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-200 and Carboplatin in Platinum-Resistant Recurrent Ovarian Cancer
NCT01690468Phase 2Terminated
- Sponsor
- Prescient Therapeutics
- Start
- Sep 2014
- Primary completion
- Dec 2019
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of triciribine in ovarian cancer, sponsored by Prescient Therapeutics. Started Sep 2014; status: terminated.
02
Drugs
triciribine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01690468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01690468.